A breast cancer survivor shares the discovery of a new kidney mass and details how she will be a smarter, more assertive ...

RASolute 302 showed daraxonrasib reduced mortality risk by 60% versus chemotherapy in previously treated metastatic PDAC, with median OS 13.2 versus 6.7 months. OPTIMA found Prosigna-defined low-risk ...

Dual PD-L1 and VEGF-A blockade with pumitamig plus chemotherapy yielded a 70% overall response rate and 100% disease control in evaluable first-line advanced NSCLC without actionable alterations.

Genotype-informed surveillance should pair colonoscopy with upper endoscopy when MLH1/MSH2 mutations or family history ...

Iza-bren improved survival and delayed disease progression versus chemotherapy in previously treated metastatic ...

Adding Opdivo (nivolumab) and Yervoy (ipilimumab) to chemotherapy did not improve how long patients with HER2-negative ...

Indications include newly diagnosed chronic-phase Ph+ CML and chronic/accelerated-phase disease after resistance or intolerance to prior therapy, including imatinib. Concomitant use with PPIs and ...

Dr. Maurie Markman, joins The Moonlight Shift to discuss precision medicine's real-world limits, oncology's cost crisis, ...

GLP-1 RA use was also tied to lower rates of immune-related side effects, caused by the immune system becoming overactive as a result of immunotherapy treatment. Patients taking GLP-1 drugs showed ...

First-in-human pancreatic cancer trial at WVU tests an implant that delivers chemotherapy directly into tumors using low-voltage electric pulses. The WVU Cancer Institute is helping lead a global ...

Kassiane Saieed explains how genomic tools provide data to help patients personalize their breast cancer treatment and survivorship. For many premenopausal women diagnosed with breast cancer, the ...

OptiTROP-Lung05 randomized 413 untreated, PD-L1 ≥1% advanced NSCLC patients without EGFR/ALK alterations to sac-TMT+pembrolizumab versus pembrolizumab; primary endpoint was PFS. Median PFS was not ...